Guardant Health Q4 Revenue Rises 39.4% to $281.3M, EPS Misses
Guardant Health reported Q4 revenue of $281.27 million, a 39.4% year-over-year increase and 0.47% above analysts’ estimates, while EPS was -$0.50 versus the -$0.42 forecast. Oncology tests totaled 79,000 versus a 75,360 estimate, screening revenue hit $35.13 million, and biopharma and data revenue reached $54.01 million, all topping consensus projections.
1. Q4 Financial Results
Guardant Health delivered Q4 revenue of $281.27 million, up 39.4% year-over-year and 0.47% above the $279.96 million consensus. EPS came in at -$0.50, missing the -$0.42 estimate by 18.1%, reflecting ongoing R&D investment pressure.
2. Business Segment Metrics
The company performed 79,000 oncology tests versus a 75,360 estimate. Oncology revenue reached $189.95 million, licensing revenue was $2.18 million, screening revenue climbed to $35.13 million, and biopharma and data revenue hit $54.01 million, each surpassing analyst projections.
3. Stock Performance and Rating
Shares have declined 7.2% over the past month compared with a 0.8% drop for the S&P 500. The stock holds a Hold rating, suggesting its performance may track the broader market near term.